Ma Junfei, Qiu Jingxuan, Wang Shuying, Ji Qianyu, Xu Dongpo, Wang Haiwang, Wu Zhiguang, Liu Qing
School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, 200093 China.
Beijing DQY Agricultural Technology Co., Ltd, Beijing, 100094 China.
Int J Pept Res Ther. 2021;27(2):1027-1042. doi: 10.1007/s10989-020-10148-x. Epub 2021 Jan 2.
() is a gram-negative spiral bacterium that caused infections in half of the world's population and had been identified as type I carcinogen by the World Health Organization. Compared with antibiotic treatment which could result in drug resistance, the vaccine therapy is becoming a promising immunotherapy option against . Further, the multi-epitope vaccine could provoke a wider immune protection to control infection. In this study, the in-silico immunogenicity calculations on 381 protein sequences of were performed, and the immunogenicity of selected proteins with top-ranked score were tested. The B cell epitopes and T cell epitopes from three well performed proteins UreB, PLA1, and Omp6 were assembled into six constructs of multi-epitope vaccines with random orders. In order to select the optimal constructs, the stability of the vaccine structure and the exposure of B cell epitopes on the vaccine surface were evaluated based on structure prediction and solvent accessible surface area analysis. Finally Construct S1 was selected and molecular docking showed that it had the potential of binding TLR2, TLR4, and TLR9 to stimulate strong immune response. In particular, this study provides good suggestions for epitope assembly in the construction of multi-epitope vaccines and it may be helpful to control infection in the future.
The online version of this article (10.1007/s10989-020-10148-x) contains supplementary material, which is available to authorized users.
（）是一种革兰氏阴性螺旋菌，它感染了世界上一半的人口，并被世界卫生组织确定为I类致癌物。与可能导致耐药性的抗生素治疗相比，疫苗疗法正成为一种有前景的针对（）的免疫疗法选择。此外，多表位疫苗可以引发更广泛的免疫保护来控制（）感染。在本研究中，对（）的381个蛋白质序列进行了计算机免疫原性计算，并测试了得分排名靠前的选定蛋白质的免疫原性。来自三种表现良好的蛋白质UreB、PLA1和Omp6的B细胞表位和T细胞表位被组装成六个随机顺序的多表位疫苗构建体。为了选择最佳构建体基于结构预测和溶剂可及表面积分析评估了疫苗结构的稳定性和疫苗表面B细胞表位的暴露情况。最后选择了构建体S1，分子对接显示它具有结合TLR2、TLR4和TLR9以刺激强烈免疫反应的潜力。特别是，本研究为多表位疫苗构建中的表位组装提供了很好的建议，并且可能有助于未来控制（）感染。
本文的在线版本（10.1007/s10989-020-10148-x）包含补充材料，授权用户可以获取。
